PET imaging of cellular proliferation

被引：106

作者：

Mankoff, DA

Shields, AF

Krohn, KA

机构：

[1] Univ Washington, Dept Radiol, Div Nucl Med, Seattle, WA 98195 USA

[2] Karmanos Canc Inst, Detroit, MI 48201 USA

[3] Wayne State Univ, Detroit, MI USA

[4] Univ Washington, Dept Radiat Oncol, Seattle, WA USA

来源：

RADIOLOGIC CLINICS OF NORTH AMERICA | 2005年 / 43卷 / 01期

关键词：

D O I：

10.1016/j.rcl.2004.09.005

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

Increased cellular proliferation is a hallmark of the cancer phenotype. Cellular proliferation imaging has a number of potential advantages over in vitro assay and glucose metabolic imaging using fluorodeoxyglucose PET, which is the mainstay of current clinical PET imaging. This article reviews the biology underlying proliferation imaging, radiopharmaceuticals used for proliferation imaging, preclinical studies of proliferation imaging, and clinical results through 2003.

引用

页码：153 / +

页数：16

共 85 条

[1] Pharmacokinetics of the thymidine analog 2′-fluoro-5-[14C]-methyl-1-β-D-arabinofuranosyluracil ([14C]FMAU) in rat prostate tumor cells [J].